<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02933697</url>
  </required_header>
  <id_info>
    <org_study_id>AXADIA - AFNET 8</org_study_id>
    <nct_id>NCT02933697</nct_id>
  </id_info>
  <brief_title>Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)</brief_title>
  <acronym>AXADIA</acronym>
  <official_title>A Safety Study Assessing Oral Anticoagulation With Apixaban Versus Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD) on Chronic Hemodialysis Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrial Fibrillation Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Atrial Fibrillation Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Study is an open-labeled, randomized controlled trial, phase IIIb. Its objective is to&#xD;
      assess the safety of the factor Xa inhibitor apixaban versus the vitamin-K antagonist (VKA)&#xD;
      phenprocoumon in patients with NVAF and ESKD on hemodialysis. The safety will be assessed by&#xD;
      means of the incidence of major and clinically relevant, non-major bleeding on&#xD;
      anticoagulation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AXADIA is an investigator-driven, prospective, parallel-group, single country, multi-center&#xD;
      phase IIIb trial to assess the safety of apixaban versus the vitamin-K antagonist&#xD;
      phenprocoumon in patients with NVAF and ESKD on hemodialysis treatment. The trial will be&#xD;
      conducted in about 25-30 sites in Germany.&#xD;
&#xD;
      The primary goal of this study is to assess the safety of two types of oral anticoagulants in&#xD;
      patients with ESKD on hemodialysis with non-valvular atrial fibrillation (NVAF). The novel&#xD;
      FXa inhibitor apixaban (at a reduced dose of 2x 2.5 mg/day) will be compared to the vitamin-K&#xD;
      antagonist (VKA) phenprocoumon (target range: International Normalized Ratio (INR) 2.0-3.0)&#xD;
      regarding bleeding rates during chronic administration for prevention of stroke or systemic&#xD;
      embolism.&#xD;
&#xD;
      The primary hypothesis of the study is that oral anticoagulation with apixaban will improve&#xD;
      the safety by significantly reducing bleeding rates in patients with ESKD on hemodialysis and&#xD;
      NVAF compared to the VKA phenprocoumon.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2017</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the safety of the factor Xa inhibitor apixaban versus a vitamin-K antagonist phenprocoumon in patients with NVAF and ESKD on hemodialysis.</measure>
    <time_frame>1-60 months</time_frame>
    <description>The safety will be assessed by means of the incidence of major and clinically relevant, non-major bleeding as well as specific bleedings in dialysis patients (e.g., after shunt removal) on anticoagulation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the efficacy of the factor Xa inhibitor apixaban with the VKA phenprocoumon regarding prevention of thromboembolic events in patients with ESKD on hemodialysis and AF</measure>
    <time_frame>1-60 months</time_frame>
    <description>The efficacy of the factor Xa inhibitor apixaban with the VKA phenprocoumon regarding prevention of thromboembolic events in patients with ESKD on hemodialysis and AF</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>End-stage Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.5 mg apixaban twice daily for 6 to 60 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin-K antagonists (Phenprocoumon)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Phenprocoumon by INR (Target: 2.0-3.0) treatment for 6 to 60 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Patients will be instructed to take one tablet of 2.5 mg twice daily: one tablet in the morning and one in the evening at approximately the same time every day (with about 12 hours gap) irrespective of the time of dialysis.</description>
    <arm_group_label>Apixaban</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenprocoumon</intervention_name>
    <description>Subjects in phenprocoumon treatment group will receive phenprocoumon individually adjusted to an INR of 2.0-3.0 as recommended in the appropriate SmPC for AF patients.</description>
    <arm_group_label>Vitamin-K antagonists (Phenprocoumon)</arm_group_label>
    <other_name>Marcumar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  End-stage kidney disease (ESKD) with chronic hemodialysis treatment 3 times per week&#xD;
             (with about at least 3.5 hours per dialysis)&#xD;
&#xD;
          -  Chronic (i.e. repeated) paroxysmal, persistent or permanent atrial fibrillation (AF)&#xD;
             or atrial flutter (AFL) documented by standard or Holter ECG on at least 2 separate&#xD;
             days before (or apart from) hemodialysis procedures&#xD;
&#xD;
          -  Increased risk of stroke or systemic embolism identified by a CHA2DS2-VASc score of 2&#xD;
             or more as an indication for oral anticoagulation&#xD;
&#xD;
          -  Patients with ischemic stroke that meet the above criteria, can be included after more&#xD;
             than 3 months if not severely handicapped (modified Rankin scale 0 or 1 of 6, i.e. no&#xD;
             symptoms or no significant disability and able to carry out all usual activities,&#xD;
             despite some symptoms (Farrell, Godwin, Richards, and Warlow (1991))&#xD;
&#xD;
          -  Males and females, aged 18 or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  AF or AFL due to reversible causes (e.g., thyrotoxicosis, pericarditis)&#xD;
&#xD;
          -  Patients with a new onset of hemodialysis within the last 3 months&#xD;
&#xD;
          -  Clinically significant (moderate or severe) aortic and mitral stenosis&#xD;
&#xD;
          -  Conditions other than AF or AFL that require chronic anticoagulation (e.g., a&#xD;
             prosthetic mechanical heart valve).&#xD;
&#xD;
          -  Active infective endocarditis&#xD;
&#xD;
          -  Any planned interventional or surgical AF or AFL ablation procedure&#xD;
&#xD;
          -  Any active bleeding&#xD;
&#xD;
          -  A serious bleeding event in the previous 6 months before screening&#xD;
&#xD;
          -  Inadequately controlled (HbA1c levels &gt;8.5%) or untreated diabetes&#xD;
&#xD;
          -  History of malignant neoplasms at high risk of current bleeding (see summary of&#xD;
             product characteristics (SmPC) of study drugs)&#xD;
&#xD;
          -  Known indication for treatment with NSAIDs (see SmPC of study drugs) - acetylsalicylic&#xD;
             acid (ASA) up to 100 mg per day is allowed&#xD;
&#xD;
          -  Known Antiphospholipid Syndrome requiring anticoagulation&#xD;
&#xD;
          -  Impaired liver function e.g., caused by active infection with HIV, HBV or HCV,&#xD;
             hepatitis or other liver damage (No limits for ALT and AST values are defined in this&#xD;
             study protocol, although mentioned in the SmPC because they are frequently elevated in&#xD;
             dialysis patients. In case of clinically relevant increase of ALT or AST level,&#xD;
             patient's eligibility is to be decided by the responsible investigator)&#xD;
&#xD;
          -  Any type of stroke within 3 months prior to baseline&#xD;
&#xD;
          -  Other indication for anticoagulation than AF or AFL&#xD;
&#xD;
          -  Valvular heart disease requiring surgery&#xD;
&#xD;
          -  A high risk of bleeding (e.g., active peptic ulcer disease, a platelet count of&#xD;
             &lt;100,000 per cubic millimeter or hemoglobin level of &lt;8 g per deciliter)&#xD;
&#xD;
          -  Documented hemorrhagic tendencies or blood dyscrasias&#xD;
&#xD;
          -  Current alcohol or drug abuse&#xD;
&#xD;
          -  Life expectancy of less than 1 year&#xD;
&#xD;
          -  Indication for dual platelet inhibition at baseline (ASA ≤ 100 mg/day is allowed,&#xD;
             clopidrogel is excluded at any dose).&#xD;
&#xD;
          -  Active infection or symptoms suggestive of COVID-19 infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Holger Reinecke, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Münster</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Jürgensmeyer, Dr.</last_name>
    <phone>0049 (0) 251 980</phone>
    <phone_ext>1346</phone_ext>
    <email>info-axadia@af-net.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simone Mähner</last_name>
    <phone>0049 (0) 251 980</phone>
    <phone_ext>1330</phone_ext>
    <email>info-axadia@af-net.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 7, 2016</study_first_submitted>
  <study_first_submitted_qc>October 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Kidney disease</keyword>
  <keyword>Anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Phenprocoumon</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

